Trial site
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida 33140, United StatesNot linked to an institution yet
- 19running trials
- 8closed trials
The trials here
What the 27 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 27 trials
- Phase 1/26 trials
- Phase 13 trials
- Phase 2/32 trials
- Phase 41 trial
- Status
- Active, not recruiting10 trials
- Recruiting8 trials
- Completed6 trials
- Terminated2 trials
- Enrolling by invitation1 trial
- Lead sponsor
- Genmab3 trials
- Celgene2 trials
- Pfizer2 trials
- Aadi Bioscience, Inc.1 trial
- Acrivon Therapeutics1 trial
- and 18 more
Running trials
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627· Phase 2· Incyte Corporation· Source
Recruiting
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
NCT06952660· Phase 4· Pfizer· Source
Active, not recruiting
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· Phase 3· Genmab· Source
Recruiting
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
NCT06463028· Phase 2· Faeth Therapeutics· Source
Contact: Medical Monitor
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025· Phase 2/3· Daiichi Sankyo· Source
Recruiting
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT05997017· Phase 2· Aadi Bioscience, Inc.· Source
Contact: Michelle McClosky
Active, not recruiting
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475· Phase 3· TransThera Sciences (Nanjing), Inc.· Source
Recruiting
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
NCT05602363· Phase 1· Carna Biosciences, Inc.· Source
Contact: Yvonne Enriquez
Active, not recruiting
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823· Phase 2· Taiho Oncology, Inc.· Source
Active, not recruiting
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931· Phase 3· Karyopharm Therapeutics Inc· Source
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· Phase 3· Gilead Sciences· Source
Enrolling by invitation
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
NCT05741242· Phase 1/2· Jaime Leandro Foundation for Therapeutic Cancer Vaccines· Source
Recruiting
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296· Phase 2· Acrivon Therapeutics· Source
Contact: Evelyn Goya
Active, not recruiting
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
NCT05141721· Phase 2/3· Seattle Project Corporation· Source
Recruiting
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352· Phase 1/2· Alliance Foundation Trials, LLC.· Source
Contact: Quality Management and Compliance
Active, not recruiting
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421· Phase 3· Pfizer· Source
Active, not recruiting
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541· Phase 1/2· Genmab· Source
Active, not recruiting
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599· Phase 1/2· Genmab· Source
Active, not recruiting
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03281954· Phase 3· NSABP Foundation Inc· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Terminated
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
NCT05631574· Phase 1· Biomea Fusion Inc.· Source
Terminated
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
NCT04791384· Phase 1/2· Criterium, Inc.· Source
Completed
A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
NCT05323656· Phase 2· Calliditas Therapeutics Suisse SA· Source
Completed
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
NCT05198804· Phase 1/2· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Source
Recruiting
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
NCT04830137· Phase 1· Nurix Therapeutics, Inc.· Source
Contact: Patient Outreach
Completed
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
NCT02360579· Phase 2· Iovance Biotherapeutics, Inc.· Source
Completed
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
NCT01996865· Phase 3· Celgene· Source
Completed
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission
NCT01757535· Phase 3· Celgene· Source
Report an error